ARS Pharmaceuticals, Inc. (SPRY)

NASDAQ: SPRY · IEX Real-Time Price · USD
7.06
-0.14 (-1.94%)
Dec 6, 2022 4:00 PM EST - Market closed
-1.94%
Market Cap 675.15M
Revenue (ttm) n/a
Net Income (ttm) -85.38M
Shares Out 35.46M
EPS (ttm) -2.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 104,854
Open 7.09
Previous Close 7.2
Day's Range 7.03 - 7.38
52-Week Range 2.8 - 7.79
Beta n/a
Analysts Sell
Price Target n/a
Earnings Date n/a

About SPRY

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California. [Read more]

Industry Biotechnology
Founded 2015
Employees 9
Stock Exchange NASDAQ
Ticker Symbol SPRY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Sell
Stock Forecasts

News

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treat...

Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting

3 weeks ago - GlobeNewsWire

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy ® in the U.S., if Approved

4 weeks ago - GlobeNewsWire

Silverback Therapeutics, Inc. announces the FDA's acceptance of ARS Pharmaceuticals' NDA for neffy® (epinephrine nasa...

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s...

1 month ago - Business Wire

SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigat...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.

1 month ago - Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TMX, VIVO, RFP, SBTX

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Other symbols: RFPTMXVIVO
2 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY

NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o...

Other symbols: HNGR
3 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBTX, IEA, PBFX, RMO

NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches o...

3 months ago - PRNewsWire

SILVERBACK THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigat...

NEW ORLEANS , Aug. 10, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

3 months ago - PRNewsWire

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBTX, IEA, PBFX, RFP

NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of...

Other symbols: RFP
3 months ago - PRNewsWire

Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTX

NEW YORK , July 27, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rate...

4 months ago - PRNewsWire

SHAREHOLDER ALERT: Weiss Law Investigates Silverback Therapeutics, Inc.

NEW YORK , July 22, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Silverback Therapeutics, Inc. ("Silverbac...

4 months ago - PRNewsWire

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Silverback Therapeutics, Inc. Merger

Wilmington, Delaware--(Newsfile Corp. - July 22, 2022) - Rigrodsky Law, P.A. is investigating Silverback Therapeutics, Inc. ("Silverback") (NASDAQ: SBTX) regarding possible breaches of fiduciary duties ...

4 months ago - Newsfile Corp

SBTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Silverback Therapeutics, Inc. Is Fair to Sh...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Silverback Therapeutics, Inc. (NASDAQ: SBTX) and ARS Pharmaceuticals, Inc. is fair to Sil...

4 months ago - Business Wire

Silverback Therapeutics to merge with San Diego biotech company developing EpiPen alternative

Less than two years after its IPO and months after shutting down its once-promising oncology program, Seattle-based Silverback Therapeutics will merge with another biotech company, San-Diego based ARS P...

4 months ago - GeekWire

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

SEATTLE & SAN DIEGO--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS Pharmaceuticals, Inc. (“ARS”) today announced that the companies have entered into a definitive ...

4 months ago - Business Wire

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delive...

6 months ago - Business Wire

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delive...

6 months ago - Business Wire

Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce

Silverback Therapeutics Inc (NASDAQ: SBTX) undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays off more than a quarter of its staff. Silverback will continu...

8 months ago - Benzinga

Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce

Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report.

8 months ago - GeekWire

Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delive...

8 months ago - Business Wire

Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

9 months ago - Business Wire

Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

10 months ago - Business Wire

Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

11 months ago - Business Wire

SBTX Final Deadline - Bronstein, Gewirtz & Grossman, LLC Reminds Silverback Therapeutics, Inc. Investors of Class Act...

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Silverback Therapeutics, Inc. ("Silverback" or t...

11 months ago - Business Wire

FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Silverback Therapeutics, Inc. Investors to Secure Counsel...

New York, New York--(Newsfile Corp. - January 4, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Silverback Therapeutics, Inc. (NASDAQ: SBTX): (1)...

11 months ago - Newsfile Corp